| 國家衛生研究院 |
2023-02-05 |
Real-world data validation of NAPOLI-1 nomogram for the prediction of overall survival in metastatic pancreatic cancer
|
Su, YY;Chiang, NJ;Yang, YH;Yen, CJ;Bai, LY;Chiu, CF;Chuang, SC;Yang, SH;Chou, WC;Chen, JS;Chiu, TJ;Chen, YY;Chan, DC;Peng, CM;Chiu, SC;Li, CP;Shan, YS;Chen, LT |
| 國立成功大學 |
2023-02 |
Real-World Data Validation of NAPOLI-1 Nomogram for the Prediction of Overall Survival in Metastatic Pancreatic Cancer
|
Su;Yung-Yeh;Chiang;Nai-Jung;Yang;Yi-Hsin;Yen;Chia-Jui;Bai;Li-Yuan;Chiu;Chang-Fang;Chuang;Shih-Chang;Yang;Shih-Hung;Chou;Wen-Chi;Chen;Jen-Shi;Chiu;Tai-Jan;Chen;Yen-Yang;Chan;De-Chuan;Peng;Cheng-Ming;Chiu;Sz-Chi;Li;Chung-Pin;Shan;Yan-Shen;Chen;Li-Tzong |
| 國立成功大學 |
2024-06 |
Real-world effectiveness and safety of 8-week glecaprevir/pibrentasvir for treatment-naive patients from Taiwan nationwide HCV registry
|
Huang;Chung-Feng;Chang;Te-Sheng;Kuo;Hsing-Tao;Huang;Chien-Wei;Mo;Lien-Ray;Tai;Chi-Ming;Tseng;Kuo-Chih;Bair;Ming-Jong;Wang;Sih-Ren;Lo;Ching-Chu;Chong;Lee-Won;Cheng;Pin-Nan;Yeh;Ming-Lun;Peng;Cheng-Yuan;Cheng;Chien-Yu;Huang;Jee-Fu;Lin;Chih-Lang;Yang;Chi-Chieh;Hsieh;Tsai-Yuan;Lee;Tzong-Hsi;Lee;Pei-Lun;Wu;Wen-Chih;Lin;Chih-Lin;Su;Wei-Wen;Yang;Sheng-Shun;Wang;Chia-Chi;Hu;Jui-Ting;Chen;Chun-Ting;Huang;Yi-Hsiang;Chang;Chun-Chao;Huang;Chia-Sheng;Chen;Guei-Ying;Kao;Chien-Neng;Liu;Chun-Jen;Lee;Mei-Hsuan;Tsai;Pei-Chien;Dai;Chia-Yen;Kao;Jia-Horng;Lin;Han-Chieh;Chuang;Wan-Long;Hung;Chao-Hung;Chen;Chi-Yi;Yu;Ming-Lung |
| 臺大學術典藏 |
2019 |
Real-world effectiveness and safety of glecaprevir/pibrentasvir in Asian patients with chronic hepatitis C
|
Hsu S.-J.; Chiu M.-C.; Fang Y.-J.; Yang T.-H.; Yu J.-J.; CHIEH-CHANG CHEN; Kuo C.-C.; Lee J.-Y.; Chen C.-H.; Chen D.-S.; Kao J.-H. |
| 臺大學術典藏 |
2022-02-22T05:34:12Z |
Real-world effectiveness and safety of glecaprevir/pibrentasvir in Asian patients with chronic hepatitis C
|
Hsu S.-J.; Chiu M.-C.; Fang Y.-J.; Yang T.-H.; Yu J.-J.; Chen C.-C.; Kuo C.-C.; Lee J.-Y.; CHIEN-HUNG CHEN; Chen D.-S.; Kao J.-H. |
| 臺大學術典藏 |
2022-02-14T06:28:47Z |
Real-world effectiveness and safety of glecaprevir/pibrentasvir in Asian patients with chronic hepatitis C
|
Hsu S.-J.; Chiu M.-C.; YU-JEN FANG; Yang T.-H.; Yu J.-J.; Chen C.-C.; Kuo C.-C.; Lee J.-Y.; Chen C.-H.; Chen D.-S.; Kao J.-H. |
| 臺大學術典藏 |
2022-02-18T08:25:58Z |
Real-world effectiveness and safety of glecaprevir/pibrentasvir in Asian patients with chronic hepatitis C
|
Hsu S.-J.; Chiu M.-C.; Fang Y.-J.; Yang T.-H.; Yu J.-J.; CHIEH-CHANG CHEN; Kuo C.-C.; Lee J.-Y.; Chen C.-H.; Chen D.-S.; Kao J.-H. |
| 臺大學術典藏 |
2022-02-23T02:12:23Z |
Real-world effectiveness and safety of glecaprevir/pibrentasvir in Asian patients with chronic hepatitis C
|
Hsu S.-J.; Chiu M.-C.; Fang Y.-J.; Yang T.-H.; Yu J.-J.; Chen C.-C.; Kuo C.-C.; Lee J.-Y.; CHIEN-HUNG CHEN; Chen D.-S.; Kao J.-H. |
| 臺大學術典藏 |
2021-09-04T05:16:49Z |
Real-world effectiveness and safety of glecaprevir/pibrentasvir in Asian patients with chronic hepatitis C
|
Hsu S.-J.; Chiu M.-C.; Fang Y.-J.; Yang T.-H.; Yu J.-J.; Chen C.-C.; Kuo C.-C.; Lee J.-Y.; Chen C.-H.; Chen D.-S.; JIA-HORNG KAO |
| 國立成功大學 |
2020-03-01 |
Real-world effectiveness and safety of ledipasvir/sofosbuvir for genotype 6 chronic hepatitis C patients in Taiwan
|
鄭斌男; 陳志州;李佩倫;邱宏志;董宏達;邱彥程 |
| 國立成功大學 |
2020-03 |
Real-world effectiveness and safety of ledipasvir/sofosbuvir for genotype 6 chronic hepatitis C patients in Taiwan
|
Chen;Jyh-Jou;Lee;Pei-Lun;Chiu;Hung-Chih;Tung;Hung-Da;Chiu;Yen-Cheng;Cheng;Pin-Nan |
| 臺大學術典藏 |
2021-05-24T07:20:28Z |
Real-world effectiveness and safety of paritaprevir/ritonavir, ombitasvir, and dasabuvir with or without ribavirin for patients with chronic hepatitis C virus genotype 1b infection in Taiwan
|
CHEN-HUA LIU; Liu C.-J.; Su T.-H.; Yang H.-C.; Hong C.-M.; Tseng T.-C.; Chen P.-J.; Chen D.-S.; Kao J.-H. |
| 臺大學術典藏 |
2021-06-25T08:10:15Z |
Real-world effectiveness and safety of paritaprevir/ritonavir, ombitasvir, and dasabuvir with or without ribavirin for patients with chronic hepatitis C virus genotype 1b infection in Taiwan
|
Liu C.-H.; Liu C.-J.; Su T.-H.; Yang H.-C.; CHUN-MING HONG; Tseng T.-C.; Chen P.-J.; Chen D.-S.; Kao J.-H. |
| 臺大學術典藏 |
2021-07-03T03:33:40Z |
Real-world effectiveness and safety of paritaprevir/ritonavir, ombitasvir, and dasabuvir with or without ribavirin for patients with chronic hepatitis C virus genotype 1b infection in Taiwan
|
Liu C.-H.; Liu C.-J.; Su T.-H.; Yang H.-C.; Hong C.-M.; Tseng T.-C.; PEI-JER CHEN; Chen D.-S.; Kao J.-H. |
| 臺大學術典藏 |
2021-07-12T02:44:33Z |
Real-world effectiveness and safety of paritaprevir/ritonavir, ombitasvir, and dasabuvir with or without ribavirin for patients with chronic hepatitis C virus genotype 1b infection in Taiwan
|
Liu C.-H; | Liu C.-J; | Su T.-H; | HUNG-CHIH YANG; | Hong C.-M; | Tseng T.-C; | Chen P.-J; | Chen D.-S; | Kao J.-H. |
| 臺大學術典藏 |
2021-09-04T05:17:09Z |
Real-world effectiveness and safety of paritaprevir/ritonavir, ombitasvir, and dasabuvir with or without ribavirin for patients with chronic hepatitis C virus genotype 1b infection in Taiwan
|
Liu C.-H.; Liu C.-J.; Su T.-H.; Yang H.-C.; Hong C.-M.; Tseng T.-C.; Chen P.-J.; Chen D.-S.; JIA-HORNG KAO |
| 臺大學術典藏 |
2022-01-24T09:31:21Z |
Real-world effectiveness and safety of paritaprevir/ritonavir, ombitasvir, and dasabuvir with or without ribavirin for patients with chronic hepatitis C virus genotype 1b infection in Taiwan
|
Liu C.-H.; CHUN-JEN LIU; Su T.-H.; Yang H.-C.; Hong C.-M.; Tseng T.-C.; Chen P.-J.; Chen D.-S.; Kao J.-H. |
| 臺大學術典藏 |
2021-03-09T01:43:23Z |
Real-world effectiveness and safety of paritaprevir/ritonavir, ombitasvir, and dasabuvir with or without ribavirin for patients with chronic hepatitis C virus genotype 1b infection in Taiwan
|
Liu C.-H.; Liu C.-J.; TUNG-HUNG SU; Yang H.-C.; Hong C.-M.; Tseng T.-C.; Chen P.-J.; Chen D.-S.; Kao J.-H. |
| 臺大學術典藏 |
2019-02-27T06:48:01Z |
Real-world effectiveness and safety of sofosbuvir and ledipasvir with or without ribavirin for patients with hepatitis C virus genotype 1 infection in Taiwan
|
Tseng, Tai-Chung;JIA-HORNG KAO;DING-SHINN CHEN;PEI-JER CHEN;CHUN-MING HONG;HUNG-CHIH YANG;TUNG-HUNG SU;CHUN-JEN LIU;CHEN-HUA LIU; CHEN-HUA LIU; CHUN-JEN LIU; TUNG-HUNG SU; HUNG-CHIH YANG; CHUN-MING HONG; Tseng, Tai-Chung; PEI-JER CHEN; DING-SHINN CHEN; JIA-HORNG KAO |
| 臺大學術典藏 |
2021-03-09T01:43:20Z |
Real-world effectiveness and safety of sofosbuvir and ledipasvir with or without ribavirin for patients with hepatitis C virus genotype 1 infection in Taiwan
|
Liu C.-H.; Liu C.-J.; TUNG-HUNG SU; Yang H.-C.; Hong C.-M.; Tseng T.-C.; Chen P.-J.; Chen D.-S.; Kao J.-H. |
| 臺大學術典藏 |
2021-05-24T07:20:25Z |
Real-world effectiveness and safety of sofosbuvir and ledipasvir with or without ribavirin for patients with hepatitis C virus genotype 1 infection in Taiwan
|
CHEN-HUA LIU; Liu C.-J.; Su T.-H.; Yang H.-C.; Hong C.-M.; Tseng T.-C.; Chen P.-J.; Chen D.-S.; Kao J.-H. |
| 臺大學術典藏 |
2021-06-25T08:10:13Z |
Real-world effectiveness and safety of sofosbuvir and ledipasvir with or without ribavirin for patients with hepatitis C virus genotype 1 infection in Taiwan
|
Liu C.-H.; Liu C.-J.; Su T.-H.; Yang H.-C.; CHUN-MING HONG; Tseng T.-C.; Chen P.-J.; Chen D.-S.; Kao J.-H. |
| 臺大學術典藏 |
2021-07-12T02:44:29Z |
Real-world effectiveness and safety of sofosbuvir and ledipasvir with or without ribavirin for patients with hepatitis C virus genotype 1 infection in Taiwan
|
Liu C.-H; | Liu C.-J; | Su T.-H; | HUNG-CHIH YANG; | Hong C.-M; | Tseng T.-C; | Chen P.-J; | Chen D.-S; | Kao J.-H. |
| 臺大學術典藏 |
2021-09-04T05:16:58Z |
Real-world effectiveness and safety of sofosbuvir and ledipasvir with or without ribavirin for patients with hepatitis C virus genotype 1 infection in Taiwan
|
Liu C.-H.; Liu C.-J.; Su T.-H.; Yang H.-C.; Hong C.-M.; Tseng T.-C.; Chen P.-J.; Chen D.-S.; JIA-HORNG KAO |
| 臺大學術典藏 |
2022-01-24T09:31:17Z |
Real-world effectiveness and safety of sofosbuvir and ledipasvir with or without ribavirin for patients with hepatitis C virus genotype 1 infection in Taiwan
|
Liu C.-H.; CHUN-JEN LIU; Su T.-H.; Yang H.-C.; Hong C.-M.; Tseng T.-C.; Chen P.-J.; Chen D.-S.; Kao J.-H. |
| 臺大學術典藏 |
2021-07-03T03:33:35Z |
Real-world effectiveness and safety of sofosbuvir and ledipasvir with or without ribavirin for patients with hepatitis C virus genotype 1 infection in Taiwan
|
Liu C.-H.; Liu C.-J.; Su T.-H.; Yang H.-C.; Hong C.-M.; Tseng T.-C.; PEI-JER CHEN; Chen D.-S.; Kao J.-H. |
| 國立成功大學 |
2019-05 |
Real-world effectiveness and safety of sofosbuvir plus daclatasvir with or without ribavirin for genotype 2 chronic hepatitis C in Taiwan
|
Cheng;Pin-Nan;Chiu;Yen-Cheng;Chien;Shih-Chieh;Chiu;Hung-Chih |
| 國立成功大學 |
2022-11 |
Real-world effectiveness and safety of sofosbuvir/velpatasvir and glecaprevir/ pibrentasvir for genotype 6 chronic hepatitis C
|
Chen;Jyh-Jou;Chiu;Yen-Cheng;Lee;Pei-Lun;Tung;Hung-Da;Chiu;Hung-Chih;Chien;Shih-Chieh;Cheng;Pin-Nan |
| 國立成功大學 |
2022 |
Real-world effectiveness and safety of sofosbuvir/velpatasvir and glecaprevir/pibrentasvir for genotype 6 chronic hepatitis C
|
Chen, J.-J.;Chiu, Y.-C.;Lee, P.-L.;Tung, H.-D.;Chiu, H.-C.;Chien, S.-C.;Cheng, P.-N. |
| 臺大學術典藏 |
2021-03-09T01:43:14Z |
Real-World Effectiveness From the Asia Pacific Rim Liver Consortium for HBV Risk Score for the Prediction of Hepatocellular Carcinoma in Chronic Hepatitis B Patients Treated With Oral Antiviral Therapy
|
Yang H.-I.; Yeh M.-L.; Wong G.L.; Peng C.-Y.; Chen C.-H.; Trinh H.N.; Cheung K.-S.; Xie Q.; TUNG-HUNG SU; Kozuka R.; Lee D.-H.; Ogawa E.; Zhao C.; Ning H.-B.; Huang R.; Li J.; Zhang J.Q.; Ide T.; Xing H.; Iwane S.; Takahashi H.; Wong C.; Wong C.; Lin C.-H.; Hoang J.; Le A.; Henry L.; Toyoda H.; Ueno Y.; Gane E.J.; Eguchi Y.; Kurosaki M.; Wu C.; Liu C.; Shang J.; Furusyo N.; Enomoto M.; Kao J.-H.; Yuen M.-F.; Yu M.-L.; Nguyen M.H. |
| 臺大學術典藏 |
2021-09-04T05:16:43Z |
Real-world effectiveness from the asia pacific rim liver consortium for hbv risk score for the prediction of hepatocellular carcinoma in chronic hepatitis b patients treated with oral antiviral therapy
|
Yang H.-I.; Yeh M.-L.; Wong G.L.; Peng C.-Y.; Chen C.-H.; Trinh H.N.; Cheung K.-S.; Xie Q.; Su T.-H.; Kozuka R.; Lee D.-H.; Ogawa E.; Zhao C.; Ning H.-B.; Huang R.; Li J.; Zhang J.Q.; Ide T.; Xing H.; Iwane S.; Takahashi H.; Wong C.; Wong C.; Lin C.-H.; Hoang J.; Le A.; Henry L.; Toyoda H.; Ueno Y.; Gane E.J.; Eguchi Y.; Kurosaki M.; Wu C.; Liu C.; Shang J.; Furusyo N.; Enomoto M.; JIA-HORNG KAO; Yuen M.-F.; Yu M.-L.; Nguyen M.H. |
| 臺大學術典藏 |
2021-06-25T08:10:12Z |
Real-world effectiveness of direct-acting antiviral agents for chronic hepatitis C in Taiwan: Real-world data
|
CHUN-MING HONG; Liu C.-H.; Su T.-H.; Yang H.-C.; Chen P.-J.; Chen Y.-W.; Kao J.-H.; Liu C.-J. |
| 臺大學術典藏 |
2021-07-03T03:33:23Z |
Real-world effectiveness of direct-acting antiviral agents for chronic hepatitis C in Taiwan: Real-world data
|
Hong C.-M.; Liu C.-H.; Su T.-H.; Yang H.-C.; PEI-JER CHEN; Chen Y.-W.; Kao J.-H.; Liu C.-J. |
| 臺大學術典藏 |
2021-03-09T01:43:11Z |
Real-world effectiveness of direct-acting antiviral agents for chronic hepatitis C in Taiwan: Real-world data
|
Hong C.-M.; Liu C.-H.; TUNG-HUNG SU; Yang H.-C.; Chen P.-J.; Chen Y.-W.; Kao J.-H.; Liu C.-J. |
| 臺大學術典藏 |
2021-05-24T07:20:16Z |
Real-world effectiveness of direct-acting antiviral agents for chronic hepatitis C in Taiwan: Real-world data
|
Hong C.-M.; CHEN-HUA LIU; Su T.-H.; Yang H.-C.; Chen P.-J.; Chen Y.-W.; Kao J.-H.; Liu C.-J. |
| 臺大學術典藏 |
2021-07-12T02:44:23Z |
Real-world effectiveness of direct-acting antiviral agents for chronic hepatitis C in Taiwan: Real-world data
|
Hong C.-M; | Liu C.-H; | Su T.-H; | HUNG-CHIH YANG; | Chen P.-J; | Chen Y.-W; | Kao J.-H; | Liu C.-J. |
| 臺大學術典藏 |
2022-01-24T09:31:06Z |
Real-world effectiveness of direct-acting antiviral agents for chronic hepatitis C in Taiwan: Real-world data
|
Hong C.-M.; Liu C.-H.; Su T.-H.; Yang H.-C.; Chen P.-J.; Chen Y.-W.; Kao J.-H.; CHUN-JEN LIU |
| 臺大學術典藏 |
2020 |
Real-world effectiveness of direct-acting antiviral agents for chronic hepatitis C in Taiwan: Real-world data
|
Liu C.-J.; Kao J.-H.; Chen Y.-W.; Chen P.-J.; Yang H.-C.; Su T.-H.; CHEN-HUA LIU; Hong C.-M. |
| 臺大學術典藏 |
2021-09-04T05:16:33Z |
Real-world effectiveness of direct-acting antiviral agents for chronic hepatitis C in Taiwan: Real-world data
|
Hong C.-M.; Liu C.-H.; Su T.-H.; Yang H.-C.; Chen P.-J.; Chen Y.-W.; JIA-HORNG KAO; Liu C.-J. |
| 嘉南藥理大學 |
2022 |
Real-world effectiveness of direct-acting antivirals in people living with human immunodeficiency virus and hepatitis C virus genotype 6 infections
|
Sun, Hsin-Yun; Cheng, Chien-Yu; Lin, Chi-Ying; Yang, Chia-Jui; Lee, Nan-Yao; Liou, Bo-Huang; Tang, Hung-Jen; Liu, Yuang-Meng; Lee, Chun-Yuan; Chen, Tun-Chieh; Huang, Yi-Chia; Lee, Yuan-Ti; Tsai, Ming-Jui; Lu, Po-Liang; Tsai, Hung-Chin; Wang, Ning-Chi; Hung, Tung-Che; Cheng, Shu-Hsing; Hung, Chien-Ching |
| 臺大學術典藏 |
2022-04-14T23:27:16Z |
Real-world effectiveness of direct-acting antivirals in people living with human immunodeficiency virus and hepatitis C virus genotype 6 infections
|
HSIN-YUN SUN; Cheng, Chien Yu; Lin, Chi Ying; Yang, Chia Jui; Lee, Nan Yao; Liou, Bo Huang; Tang, Hung Jen; Liu, Yuang Meng; Lee, Chun Yuan; Chen, Tun Chieh; Huang, Yi Chia; Lee, Yuan Ti; Tsai, Ming Jui; Lu, Po Liang; Tsai, Hung Chin; Wang, Ning Chi; Hung, Tung Che; Cheng, Shu Hsing; CHIEN-CHING HUNG |
| 臺大學術典藏 |
2022-05-25T05:47:44Z |
Real-world effectiveness of direct-acting antivirals in people living with human immunodeficiency virus and hepatitis C virus genotype 6 infections
|
HSIN-YUN SUN; Cheng, Chien-Yu; Lin, Chi-Ying; Yang, Chia-Jui; Lee, Nan-Yao; Liou, Bo-Huang; Tang, Hung-Jen; Liu, Yuang-Meng; Lee, Chun-Yuan; Chen, Tun-Chieh; Huang, Yi-Chia; Lee, Yuan-Ti; Tsai, Ming-Jui; Lu, Po-Liang; Tsai, Hung-Chin; Wang, Ning-Chi; Hung, Tung-Che; Cheng, Shu-Hsing; Hung, Chien-Ching |
| 臺大學術典藏 |
2022-09-15T05:42:28Z |
Real-world effectiveness of direct-acting antivirals in people living with human immunodeficiency virus and hepatitis C virus genotype 6 infections
|
Sun H.-Y.; Cheng C.-Y.; Lin C.-Y.; Yang C.-J.; Lee N.-Y.; Liou B.-H.; Tang H.-J.; Liu Y.-M.; Lee C.-Y.; Chen T.-C.; Huang Y.-C.; Lee Y.-T.; Tsai M.-J.; Lu P.-L.; Tsai H.-C.; Wang N.-C.; Hung T.-C.; Cheng S.-H.; CHIEN-CHING HUNG |
| 國立成功大學 |
2022 |
Real-world effectiveness of direct-acting antivirals in people living with human immunodeficiency virus and hepatitis C virus genotype 6 infections
|
Sun, H.-Y.;Cheng, Cheng C.-Y.;Lin, C.-Y.;Yang, C.-J.;Lee, N.-Y.;Liou, B.-H.;Tang, H.-J.;Liu, Y.-M.;Lee, C.-Y.;Chen, T.-C.;Huang, Y.-C.;Lee, Y.-T.;Tsai, M.-J.;Lu, P.-L.;Tsai, H.-C.;Wang, N.-C.;Hung, T.-C.;Cheng, S.-H.;Hung, C.-C. |
| 臺大學術典藏 |
2022-02-22T05:34:11Z |
Real-world effectiveness of glecaprevir/pibrentasvir and ledipasvir/sofosbuvir for mixed genotype hepatitis C infection: A multicenter pooled analysis in Taiwan
|
Chiu W.-N.; Hung C.-H.; Lu S.-N.; Chen M.-Y.; Tung S.-Y.; Wei K.-L.; Lu C.-K.; CHIEN-HUNG CHEN; Hu T.-H.; Hu J.-H.; Chen W.-M.; Chang T.-S. |
| 臺大學術典藏 |
2022-02-23T02:12:22Z |
Real-world effectiveness of glecaprevir/pibrentasvir and ledipasvir/sofosbuvir for mixed genotype hepatitis C infection: A multicenter pooled analysis in Taiwan
|
Chiu W.-N.; Hung C.-H.; Lu S.-N.; Chen M.-Y.; Tung S.-Y.; Wei K.-L.; Lu C.-K.; CHIEN-HUNG CHEN; Hu T.-H.; Hu J.-H.; Chen W.-M.; Chang T.-S. |
| 國立成功大學 |
2021 |
Real-world effectiveness of hyperbaric oxygen therapy for delayed neuropsychiatric sequelae after carbon monoxide poisoning
|
Liao, S.-C.;Shao, Shao S.-C.;Yang, K.-J.;Yang, C.-C. |
| 臺大學術典藏 |
2019-07-26T06:32:02Z |
Real-world effectiveness of medications on survival in patients with COPD-heart failure overlap
|
Yang K.-Y.;Pau-Chung Chen;Su W.-J.;Su K.-C.;Chou K.-T.;Tsai Y.-H.;Perng D.-W.;Yang Y.-H.;Su V.Y.-F.; Su V.Y.-F.; Yang Y.-H.; Perng D.-W.; Tsai Y.-H.; Chou K.-T.; Su K.-C.; Su W.-J.; PAU-CHUNG CHEN; Yang K.-Y. |
| 臺大學術典藏 |
2022-03-31T02:38:31Z |
Real-world effectiveness of medications on survival in patients with COPD-heart failure overlap
|
Su V.Y.-F.; Yang Y.-H.; Perng D.-W.; Tsai Y.-H.; Chou K.-T.; Su K.-C.; Su W.-J.; PAU-CHUNG CHEN; Yang K.-Y. |
| 臺大學術典藏 |
2022-05-03T03:02:17Z |
Real-world effectiveness of second-line Afatinib versus chemotherapy for the treatment of advanced lung squamous cell carcinoma in immunotherapy-na?ve patients
|
Chen Y.-Y.; Chang S.-C.; Chang C.-Y.; Chang C.-F.; Lai Y.-C.; Wei Y.-F.; CHUNG-YU CHEN |
